	7/20/2005 15:58 TEL 650 327 0960 J M Schiff 07/19/05 10:32 FAX 949 833 8664 MEYER PHARMACEUTICALS						图 001 图 002	
(IPE)				RANSMITTA			_ ,	
Complete and send th	form, together wi				ISSUE			
JUL 2 0 2005	in)			P.O. Box	1450	nia 22313-1450		
\ <u>P</u>	3		or <u>Fa</u>	x (703) 746-	-4000			
INSTRUCTIONS: This for appropriate All further con- indicated unless parametric maintenance fee notifications	P should be used for transferondence including the clow or directed otherwise	smitting the ISSU Patent, advance or in Block 1, by (a	E FEB and PU ders and notific) specifying a n	BLICATION FEE ation of maintenan ew correspondence	if require nce fees will e address; a	ed). Blocks I through 5 s il be mailed to the current md/or (b) indicating a sep	hould be completed where correspondence address as arate "FEE ADDRESS" for	
	ADDRESS (Note: Use Block I for			Note: A cert	dificate of m	nailing can only be used f	or domestic mailings of the for any other accompanying	
755	ı	G.		papers. Each have its own	edditional certificate	paper, such as an assignm of mailing or transmission.	ent or formal drawing, must	
MEYER PHARM 1761 KAISER AVE	I hereby cert States Postal	Certificate of Mailing or Transmission I hereby certify that this Fee(a) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (703) 746-4000, on the date indicated below.						
IRVINE, CA 92614	•			addressed to transmitted to	the Mail o the USPT	Stop ISSUE FEE address O (703) 746-4000, on the	above, or being facsimile late indicated below.	
					MICHA	EL SOUTP	(Depositor's name)	
07/21/2005 TBESHAH2 0000	07/21/2005 TBESHAH2 00000022 503320 09162648						(Signature)	
1 FC+2501 700.00 DA					٦٧	July 20, 2005	(Date)	
02 FC: ROBLICATION NO.24.06	DO FILING DATE		FIRST NAMED I		'	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/162,648 09/29/1998 JOHN C. HISERODT 9087 TITLE OF INVENTION: CANCER IMMUNOTHERAPY USING ALLOSTIMULATED CELLS IN A MULTIPLE SEQUENTIAL IMPLANTATION STRATEGY								
TITLE OF INVENTION: CA	NCER IMMUNOTHERA	PY USING ALLOS	SIMULAIED	CELLS IN A MUL	TIPLE SEC	QUENTIAL IMPLANTAT	ION STRATEGY	
		1.	•		1			
APPLN. TYPE	SMALL ENTITY	ISSUE FI	E	PUBLICATION F	RE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	YES	\$700		\$0		\$700	07/21/2005	
EXAMINER ART U			IT	CLASS-SUBCLA	SS			
CHEN, SHIN LIN 1632 424-093100								
 Change of correspondence CFR 1.363). 	address or indication of "Fo	ee Address" (37		on the patent from		J. Mick	neel Schiff	
Change of correspondence address (or Change of Correspondence or agents OR, alternatively,								
"Fee Address" indication PTO/SB/47; Rev 03-02 or Number is required.	2 registered p	name of a single firm (having as a member a cd attorney or agent) and the names of up to ered patent attorneys or agents. If no name is o name will be printed.						
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)								
PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.								
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)								
MEYER PHARMACEUTICALS LLC IRVINE, CA								
Please check the appropriate a	,,,				al Corp	oration or other private gro	up entity Government	
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed.								
Publication Fee (No sm	Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached.							
Advance Order - # of C	Copies	<u> </u>	The Director Deposit Account	is hereby authoriz	zed by char	ge the required fee(s), or (enclose an extra co	predit any overpayment, to	
5. Change in Entity Status (fi	ALL ENTITY status. See 3) 7 CFR 1.27.	b. Applicant	is no longer claimir	ng SMALL	ENTITY status. Sec 37 CI	R 1.27(g)(2).	
The Director of the USPTO is NOTE: The Issue Fee and Pub interest as shown by the record	requested to apply the Issu- lication Fee (if required) w is of the United States Pate	e Fee and Publicati ill not be accepted at and Trademark C	on Fee (if any) o from anyone oth Office.	r to re-apply any p or than the applica	neviously p	aid issue fee to the applicated attorney or agent; or the	ion identified above. e assignee or other party in	
Authorized Signature	Wdill_	T		Date		uly 20, 2005		
Typed or printed name		Michael Schif	+	Reg	istration No	40 253		
This collection of information is required by 37 CFR 1.311. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Tradsmark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.								
Alexandria, Virginia 22313-14: Under the Paperwork Reduction								
PTOL-85 (Rev. 12/04) Approv		•	OMB 0651-00			aark Office; U.S. DEPART		